Barbara Lopez Kunz Takes the Reins as DIA's Global Chief Executive

HORSHAM, Pa.—DIA today announced that Barbara Lopez Kunz has begun leading the organization as global chief executive. Kunz brings her exceptional worldwide leadership experience to DIA as former president of the Global Health and Life Sciences business at Battelle, an international science and technology nonprofit organization that explores emerging areas of science, develops and commercializes technology, and manages laboratories.

"DIA is excited to have Barbara now leading the way and utilizing her international knowledge and leadership skills to ensure that DIA remains the global forum fostering innovation to raise the level of health and well-being worldwide," DIA President Minnie Baylor-Henry said. "Barbara has a remarkably successful track record of growing businesses that are based on innovation in science and technology and implementing globally effective strategies, and we are looking forward to her leadership and guidance."

In her role with Battelle, Kunz transformed the Global Health and Life Sciences business through strategic investments, alliance development and technology commercialization, increasing the number of research collaborations with industrial, government and academic sponsors. She has also held senior roles at Thermo Fisher Scientific (formerly Fisher Scientific International), Croda International (formerly ICI), DuPont and PPG Industries, after starting her career as a research scientist.

A leader on numerous corporate and nonprofit boards, she has presided over the board of The Ohio State University Wexner Medical Center and is a trustee of both The Research Institute at Nationwide Children's Hospital and BioOhio, the statewide organization stimulating economic development in the bioscience community. Kunz is a member of the Healthcare Businesswomen's Association Ohio chapter advisory board.

"I am excited to begin leading DIA into its 50th year, and build upon nearly a half century of momentum in advancing innovation worldwide. The foundation is in place to apply my knowledge of patient needs and the health care community and to fortify DIA's significant role in transferring vital information across the globe," Kunz said.

For more information, please go to www.diahome.org. To arrange an interview with Kunz or to request a headshot or complete biography, please contact Eric Rosen at 215.290.9153 or [email protected].  

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at www.diahome.org and follow DIA at: LinkedInTwitterYouTubeFacebookFlickr andPinterest.

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.